Aridis Pharma Stock Rallied 56.3 percent on Drug Trial Results - AskTraders

IMAB Stock  USD 0.93  0.02  2.11%   
About 62% of I Mab's investor base is looking to short. The analysis of the overall investor sentiment regarding I Mab suggests that many traders are alarmed. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
  
Aridis Pharma Stock Rallied 56.3 percent on Drug Trial Results AskTraders

Read at news.google.com
Google News at Macroaxis
  

I Mab Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

I Mab Fundamental Analysis

We analyze I Mab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of I Mab using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of I Mab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

I Mab is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

I Mab Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with I Mab stock to make a market-neutral strategy. Peer analysis of I Mab could also be used in its relative valuation, which is a method of valuing I Mab by comparing valuation metrics with similar companies.

Peers

I Mab Related Equities

GLUEMonte Rosa   13.72   
0%
100.0%
BGNEBeiGene   4.29   
0%
31.0%
NRIXNurix Therapeutics   4.15   
0%
30.0%
LYELLyell Immunopharma   3.26   
0%
23.0%
CGEMCullinan Oncology   2.75   
0%
20.0%
FHTXFoghorn Therapeutics   2.57   
0%
18.0%
BPMCBlueprint Medicines   1.35   
0%
9.0%
STTKShattuck Labs   0.92   
0%
6.0%
DSGNDesign Therapeutics   0.50   
0%
3.0%
KRYSKrystal Biotech   0.26   
0%
1.0%
KYMRKymera Therapeutics   0.02   
1.0%
0%
ASNDAscendis Pharma   0.18   
1.0%
0%
AKROAkero Therapeutics   0.22   
1.0%
0%
APLSApellis Pharmaceuticals   0.62   
4.0%
0%
RVMDRevolution Medicines   1.25   
9.0%
0%
IMVTImmunovant   1.84   
13.0%
0%
ERASErasca   2.05   
14.0%
0%

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account